Biohaven Pharmaceutical Capital Lease Obligations Over Time
| BHVN Stock | USD 43.68 1.06 2.37% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Biohaven Pharmaceutical Performance and Biohaven Pharmaceutical Correlation. Biohaven |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capital Lease Obligations Analysis
Compare Biohaven Pharmaceutical and related stocks such as Immunome, Inhibrx, and AgeX Therapeutics Capital Lease Obligations Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMNM | 626 K | 626 K | 626 K | 626 K | 626 K | 626 K | 626 K | 626 K | 626 K | 239 K | 0.0 | 317 K | 293 K | 1.6 M | 1.7 M |
| INBX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.8 M | 8.2 M | 6.7 M | 5 M | 3.2 M | 4.9 M |
| DAWN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 402 K | 220 K | 813 K | 408 K | 405.5 K |
| TERN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 M | 603 K | 662.9 K |
| XFOR | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 5.3 M | 5.9 M | 4.8 M | 3.7 M | 4.9 M |
| INZY | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 3.4 M | 2.6 M | 1.8 M | 2.5 M |
| MREO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 11.9 M | 1.8 M | 2.4 M | 1.7 M | 1.6 M | 2.4 M |
| APLS | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 18.9 M | 21.2 M | 20 M | 17.9 M | 20.3 M |
| BPMC | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 16.3 M | 14.6 M | 95.9 M | 89.6 M | 111.4 M | 103.4 M | 93.7 M | 72.6 M |
| KYMR | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 21.2 M | 18 M | 18 M | 17.3 M | 84.7 M | 88.9 M |
| RVMD | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 147 K | 172 K | 32.7 M | 66.6 M | 64.2 M | 87.9 M | 92.3 M |
| CCCC | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 13.7 M | 12.9 M | 32.1 M | 75.7 M | 71 M | 40.3 M |
| AGIO | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 105.2 M | 97.1 M | 85.7 M | 72 M | 75.8 M |
| NRIX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13 M | 12 M | 30.6 M | 35.2 M | 37 M |
Biohaven Pharmaceutical and related stocks such as Immunome, Inhibrx, and AgeX Therapeutics Capital Lease Obligations description
Biohaven Pharmaceutical capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Biohaven Pharmaceutical asset purchases. For example, Biohaven Pharmaceutical can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Biohaven Pharmaceutical control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.My Equities
My Current Equities and Potential Positions
| Biohaven Pharmaceutical Holding | BHVN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Connecticut; U.S.A |
| Exchange | New York Stock Exchange |
USD 43.68
Check out Biohaven Pharmaceutical Performance and Biohaven Pharmaceutical Correlation. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Biohaven Pharmaceutical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.